Our Clinical Studies
Advancing wellness care through research, innovation, and clinical insight.
Where Innovation Meets Real Results
GLP-1s may offer ‘real impact’ for treating alcohol and substance use disorders
GLP-1s hold promise as a potential treatment for alcohol and substance use disorders, according to...
Tirzepatide Tops TRT for Men With Hypogonadism and Obesity
In a study of 83 men with obesity, functional hypogonadism, and insulin resistance, those treated...
Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obe
Tirzepatide (TZP), a dual agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors,...
A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity
FDA approval of Wegovy to lower stroke, heart attack risk makes around 3.6M Medicare patients...
Clinical Insight on Semaglutide for Chronic Weight Management in Adults
The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to...
Do Patients on Anti-Obesity Drugs Decrease Alcohol Use?
Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated with decreased...
Glycine: The Smallest Anti-Inflammatory Micronutrient
In this review, we emphasize that glycine exerts its anti-inflammatory effects throughout the modulation of...
The Growing Scientific Case for Using Ozempic and other GLP-1s to Treat Opioid, Alcohol, and Nicotine
Evidence that GLP-1 treatments like Ozempic and Mounjaro have strong anti-addictive effects across substances and...
Semaglutide Eligibility Across All Current Indications for US Adults
Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023,...
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor
Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual...
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Coh
Concerns have been raised that glucagon-like peptide 1 receptor agonists (GLP1-RAs) may increase the risk...
Early Intervention Central to Treating Muscle Mass Loss in Patients Losing Weight With GLP-1 Meds
With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only...
GLP-1s Show No Increased Risk for Thyroid Cancer
“While we cannot rule out [developments] 20 years from now, we can say that we...
